中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

57 records (took 0.023 seconds)

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING CT45
    51.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING CT45 有权

    公开(公告)号：US20230057987A1

    公开(公告)日：2023-02-23

    申请号：US17874711

    申请日：2022-07-27

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Sara YOUSEF ,  Fabian BRUNK ,  Andreas MORITZ ,  Sebastian BUNK ,  Claudia WAGNER ,  Dominik MAURER ,  Felix UNVERDORBEN

    IPC: C07K16/30 ,  C07K14/725 ,  G01N33/574

    Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.

    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
    56.
    发明申请
    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS 审中-公开

    公开(公告)号：US20190309042A1

    公开(公告)日：2019-10-10

    申请号：US16403058

    申请日：2019-05-03

    Applicant: IMMATICS BIOTECHNOLOGIES GMBH

    Inventor： Dominik MAURER ,  Sebastian BUNK ,  Leonie ALTEN

    IPC: C07K14/725 ,  A61K35/17 ,  C07K14/435 ,  C12N15/10 ,  A61K35/12 ,  C12N15/09 ,  A61K35/66

    Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Patent Agency Ranking